Reimbursement of treatment for cystic fibrosis extended to children aged 6 to 11

The Minister indicates that he has reached an agreement with Inami (the National Institute for Disability Health Insurance) and the American pharmaceutical company Vertex. The drug has also been reimbursed for patients over the age of 12 since September. This new agreement makes it possible to guarantee the best possible care to more than 140 children under the age of 12 suffering from cystic fibrosis, specifies the minister. It will therefore no longer be necessary to submit an application to the College of Orphan Drugs, which reduces the period of uncertainty for the patient and the doctor while waiting for reimbursement to be approved. Cystic fibrosis is a serious disease that has a major impact on the burden of disease and on the quality of life of patients. Several clinical studies show that the drug Kaftrio optimizes lung function, reduces the use of antibiotics and improves the quality of life of patients. The drug Kalydeco allows him to restore the salt-water balance in the respiratory tract in order to protect the lungs. (Belga)